EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum Levels of IFABP2 and Differences in Lactobacillus and Porphyromonas gingivalis Abundance on Gut Microbiota Are Associated with Poor Therapeutic Response in Rheumatoid Arthritis: A Pilot Study

Oscar Zaragoza-García iD, Natividad Castro-Alarcón, Gloria Pérez-Rubio iD, Ramcés Falfán-Valencia iD, Olivia Briceño, José Eduardo Navarro-Zarza, Isela Parra-Rojas, Mario Tello iD, Iris Paola Guzmán-Guzmán iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24031958 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Oscar Zaragoza-García und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemical-Biological Sciences, Autonomous University of Guerrero, Chilpancingo 39087, Mexico. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Gastrointestinal Microbiome, Lactobacillus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intestinal dysbiosis is related to the physiopathology and clinical manifestation of rheumatoid arthritis (RA) and the response to pharmacologic treatment. The objectives of this study were (1) to analyze the effect of conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) on the abundance of gut microbiota’s bacteria; (2) to evaluate the relationship between the differences in microbial abundance with the serum levels of intestinal fatty-acid binding protein 2 (IFABP2), cytokines, and the response phenotype to csDMARDs therapy in RA. A cross-sectional study was conducted on 23 women diagnosed with RA. The abundance of bacteria in gut microbiota was determined with qPCR. The ELISA technique determined serum levels of IFABP2, TNF-α, IL-10, and IL-17A. We found that the accumulated dose of methotrexate or prednisone is negatively associated with the abundance of Lactobacillus but positively associated with the abundance of Bacteroides fragilis. The Lactobacillus/Porphyromonas gingivalis ratio was associated with the Disease Activity Score-28 for RA with Erythrocyte Sedimentation Rate (DAS28-ESR) (r = 0.778, p = 0.030) and with the levels of IL-17A (r = 0.785, p = 0.027) in the group treated with csDMARD. Moreover, a relation between the serum levels of IFABP2 and TNF-α (r = 0.593, p = 0.035) was observed in the group treated with csDMARD. The serum levels of IFABP2 were higher in patients with secondary non-response to csDMARDs therapy. In conclusion, our results suggest that the ratios of gut microbiota’s bacteria and intestinal permeability seems to establish the preamble for therapeutic secondary non-response in RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidGastrointestinal MicrobiomeLactobacillusFemaleHumansCross-Sectional StudiesInterleukin-17Pilot ProjectsPorphyromonas gingivalisTumor Necrosis Factor-alphaIntestinesCell Membrane PermeabilityFatty Acid-Binding Proteins

Stichwörter der Autor:innen

gut microbiotaintestinal fatty-acid binding protein 2intestinal permeabilitynon-responserheumatoid arthritistherapy

Substanzen

Antirheumatic AgentsInterleukin-17Tumor Necrosis Factor-alphaFABP2 protein, humanFatty Acid-Binding Proteins

Autor:innen und Institutionen

  • Faculty of Chemical-Biological Sciences, Autonomous University of Guerrero, Chilpancingo 39087, Mexico.
  • HLA Laboratory, National Institute of Respiratory Diseases Ismael Cosío Villegas, Mexico City 14080, Mexico.
  • Infectious Diseases Research Center, National Institute of Respiratory Diseases Ismael Cosío Villegas, Mexico City 14080, Mexico.
  • Department of Medical Internal, General Hospital Raymundo Abarca Alarcón, Chilpancingo 39019, Mexico.
  • Bacterial Metagenomics Laboratory, Faculty of Chemistry and Biology, University of Santiago of Chile, Santiago 8320000, Chile.

ORCID-Profile: Oscar Zaragoza-García, Gloria Pérez-Rubio, Ramcés Falfán-Valencia, Mario Tello, Iris Paola Guzmán-Guzmán

Zitieren

APA

Zaragoza-García, O., Castro-Alarcón, N., Pérez-Rubio, G., Falfán-Valencia, R., Briceño, O., Navarro-Zarza, J. E., Parra-Rojas, I., Tello, M., & Guzmán-Guzmán, I. P. (2023). Serum Levels of IFABP2 and Differences in Lactobacillus and Porphyromonas gingivalis Abundance on Gut Microbiota Are Associated with Poor Therapeutic Response in Rheumatoid Arthritis: A Pilot Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24031958

Vancouver

Zaragoza-García O, Castro-Alarcón N, Pérez-Rubio G, Falfán-Valencia R, Briceño O, Navarro-Zarza JE, et al. Serum Levels of IFABP2 and Differences in Lactobacillus and Porphyromonas gingivalis Abundance on Gut Microbiota Are Associated with Poor Therapeutic Response in Rheumatoid Arthritis: A Pilot Study. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24031958

BibTeX
@article{ZaragozaGarca2023,
  author = {Zaragoza-García, Oscar and Castro-Alarcón, Natividad and Pérez-Rubio, Gloria and Falfán-Valencia, Ramcés and Briceño, Olivia and Navarro-Zarza, José Eduardo and Parra-Rojas, Isela and Tello, Mario and Guzmán-Guzmán, Iris Paola},
  title = {Serum Levels of IFABP2 and Differences in Lactobacillus and Porphyromonas gingivalis Abundance on Gut Microbiota Are Associated with Poor Therapeutic Response in Rheumatoid Arthritis: A Pilot Study},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24031958}
}
Kostenlos starten →